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David R. Adams,22,23 Carlos Casasnovas,1,2,4 Heidi L. Rehm,13 Heather C. Mefford,24
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Phosphoinositides are lipids that play a critical role in processes such as cellular signalling, ion channel activity
and membrane trafficking. When mutated, several genes that encode proteins that participate in the metabolism
of these lipids give rise to neurological or developmental phenotypes. PI4KA is a phosphoinositide kinase that is
highly expressed in the brain and is essential for life.
Here we used whole exome or genome sequencing to identify 10 unrelated patients harbouring biallelic variants in
PI4KA that caused a spectrum of conditions ranging from severe global neurodevelopmental delay with hypomye-
lination and developmental brain abnormalities to pure spastic paraplegia. Some patients presented immunologic-
al deficits or genito-urinary abnormalities. Functional analyses by western blotting and immunofluorescence
showed decreased PI4KA levels in the patients’ fibroblasts. Immunofluorescence and targeted lipidomics indicated
that PI4KA activity was diminished in fibroblasts and peripheral blood mononuclear cells.
In conclusion, we report a novel severe metabolic disorder caused by PI4KA malfunction, highlighting the import-
ance of phosphoinositide signalling in human brain development and the myelin sheath.
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Introduction
Phosphoinositide lipids at the plasma membrane, which are
important determinants of membrane identity, play roles in cell
signalling, controlling cell shape and motility and thus also affect
the interaction of cells with their environment.1 Phosphoinositide
metabolism at the plasma membrane begins with the phosphoryl-
ation of phosphatidylinositol (PI) to PI(4)P, which is later further
phosphorylated to PI(4,5)P2 and PI(3,4,5)P3. This first step is cata-
lysed by phosphatidylinositol 4 kinase A (PI4KA, MIM *600286) and
is regulated by FAM126A and TTC7, which are subunits of the
same complex.2,3 Animal models in which PI4KA homologues
are inactivated show profound abnormalities: downregulation of
Pi4ka expression in zebrafish leads to multiple developmental
defects affecting the brain, heart, trunk and most prominently the
loss of pectoral fins, while the Pi4ka orthologue knockout is lethal
in flies, mice and yeast.4–7
It is intriguing that pathogenic variants in FAM126A, a gene that
encodes another partner of the PI4KA/TTC7/FAM126A protein com-
plex, cause hypomyelinating leukodystrophy [hypomyelination and
congenital cataracts(HCC); MIM #610532], with the main pathogenic
mechanism of which is defective PI(4)P production in oligodendro-
cytes, a process coregulated by the myelin basic protein (MBP).2,8
Notably, mutations in other genes that encode proteins that are
involved in PI metabolism are associated with neurodevelopmental
disorders. For instance, variants in the PIK3CA, PIK3R2, AKT3, and
FIG4 genes have been linked to the development of polymicrogyria,
which can be associated or not with megalencephaly and capillary
malformation,5,9–12 and PI4K2A variants have been associated with
intellectual disability and epilepsy.13
In this study, we identified 10 patients from unrelated families
carrying biallelic variants in PI4KA that caused a spectrum of con-
ditions ranging from severe global neurodevelopmental delay with
hypomyelination/delayed myelination and developmental brain
abnormalities to pure spastic paraplegia. Analysis of protein
structure by 3D modelling and functional studies using western
blotting, immunofluorescence and targeted lipidomic studies of
the PI4KA pathway in patient cells were performed to confirm the
pathogenicity of the identified variants.
Materials and methods
Genetic studies and variant assessment
We identified PI4KA variants in probands by whole-exome or
whole-genome sequencing in clinical diagnostic or research
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settings. Candidate variants were validated by Sanger sequencing
and tested for co-segregation in all family members except for
Patient 5’s mother (unavailable). The Genome Aggregation
Database (gnomAD v.2.1.1; https://gnomad.broadinstitute.org/;
accessed 30 November 2020) was used to determine variant fre-
quency in control populations. Variants were annotated with
ANNOVAR. High-quality variants with an effect on the coding se-
quence or splice site regions with a frequency lower than 0.01
were retrieved from public databases (gnomAD and in-house data-
bases). The functional impact of variants was analysed with vari-
ous prediction tools, including PolyPhen-2, M-CAP, CADD,
MutationTaster and LRT pred. Sequence alignment was performed
using ClustalOmega (https://www.ebi.ac.uk/tools/msa/clustalo/;
accessed 30 November 2020) with sequences extracted from NCBI
databases. The PI4KA complex (6bq1 template from the RCSB PDB
database)3 was visualized with PyMOL version 2.2.3 (https://www.
pymol.org; accessed 30 November 2020).
Patient recruitment
We obtained genotypic and phenotypic information from patients
with probable pathogenic PI4KA variants (after in silico criteria),
from different hospitals identified with GeneMatcher.14 All
patients were analysed by the neurologists and/or clinical geneti-
cists of their respective referral centre, who determined the para-
clinical analyses to be performed in each case. We reviewed
clinical information related to neurodevelopment, growth parame-
ters, neurological manifestations, behaviour, dysmorphology, and
the results of other exams. Hypomyelination was diagnosed when
neuroimaging evidenced mildly elevated hyperintensity of most
cerebral white matter in T2-weighted images and mild hypointen-
sity, isointensity or mild hyperintensity relative to the cortex in
T1-weighted images.
15 Blood samples were obtained using stand-
ard methods. Written informed consent for genetic testing and
publication of the clinical information, including clinical pictures,
was obtained from the parents or legal guardians of each patient
according to the Declaration of Helsinki.
The research project was approved by the Clinical Research
Ethics Committees of IDIBELL Institute (Patients 1 and 9, PR076/14),
VHIR Institute [Patient 2, PR(AG)223/2017], CHU Bordeaux (Patient
4, Comité de Protection des Personnes Bordeaux—Outre Mer III),
the Broad Institute (Patient 5, Partners IRB Protocol #:2016P001422),
the University of Washington (Patient 6, #28853), Città della Salute
e della Scienza University Hospital (Patient 7, n. 0060884), the
Comitato Etico Brianza (Patient 8; Monza, Italy; PID-GENMET), the
IIGM Institute (Patient 10, Comité de Ética de la Investigación con
Medicamentos, CEIm) and the Montpellier Local Ethics Committee
(Patient 3).
Western blotting
Human fibroblasts were homogenized in RIPA buffer (150 mM
NaCl, 1% NonidetTM P40, 0.5% sodium deoxycholate, 0.1% SDS, and
50 mM Tris, pH 8.0), sonicated for 1 min at 4C, centrifuged for
10 min at 1000g mixed with 4 NuPAGE LDS Sample Buffer
(Invitrogen) and heated for 5 min at 100C. Protein concentrations
were quantified using a BCA protein assay kit (Thermo Fisher
Scientific). Twenty-five micrograms of each protein sample was
subjected to polyacrylamide gel electrophoresis for 30 min at 100 V
and for 1 h at 120 V in NuPAGE MOPS SDS Running Buffer
(Invitrogen) supplemented with 5 mM sodium bisulfite (Ref.
243973, Sigma-Aldrich). The proteins were transferred to nitrocel-
lulose membranes. After blocking with 5% bovine serum albumin
(BSA, Sigma-Aldrich) in 0.05% TBS-Tween (TBS-T) for 1 h at room
temperature, the membranes were incubated with primary
antibodies for 2 h at room temperature. Following incubation with
secondary antibodies for 1 h at room temperature, the proteins
were detected with the ChemidocTM Touch Imaging System (Bio-
Rad). The bands were quantified with ImageLab (Bio-Rad). The pri-
mary antibodies that were used were anti-PI4KA (12411-1-AP
Proteintech) and anti-b-Actin (A2228, Sigma). The secondary anti-
bodies that were used were polyclonal goat anti-mouse (P0447,
Dako Cytomation) and polyclonal goat anti-rabbit (P0448, Dako
Cytomation). The unmodified full-length blot is shown in
Supplementary Fig. 3.
Immunofluorescence
A total of 150 000 cells were seeded on coverslips in wells contain-
ing 2 ml of 10% formalin and fixed in for 30 min at room tempera-
ture. To permeabilize and block the cells, the coverslips were
incubated for 20 min at room temperature in blocking buffer (1%
BSA, 0.2% powdered milk, 2% NCS, 0.1 M glycine, and 0.1% TritonTM
X-100). The cells were immunostained with primary antibodies for
2 h at room temperature. Following incubation with secondary
antibodies for 1 h at room temperature, the slides were mounted
using MowiolVR . Confocal images were acquired using a Leica TCS
SL laser scanning confocal spectral microscope (Leica
Microsystems) and analysed with ImageJ (NIH, USA). The primary
antibodies that were used were anti-PI4KA (12411-1-AP,
Proteintech) and anti-PI(4)P (Z-P004, Echelon Biosciences Inc.). The
secondary antibodies that were used were Alexa FluorVR 555-conju-
gated goat anti-rabbit IgG (A-21428, Invitrogen) and Alexa FluorVR
488-conjugated goat anti-mouse IgG (A-11001, Invitrogen).
Lipidomics analysis
Peripheral blood mononuclear cells (PBMCs) were isolated from
whole blood using standard methods. Quantification of phosphoi-
nositide species was performed at ATK-Analytics Innovation and
Discovery using 200 lg of TCA-precipitated PBMCs as the starting
material. Lipids were extracted and derivatized using TMS-
Diazomethane prior to mass spectrometry, as described previous-
ly.16,17 PI 17:0 and 20:4 and PI(4)P 17:0 and 20:4 (LM1502, LM1901,
Avanti Polar Lipids) were used in parallel as internal standards.
The results were analysed using MassLynx software.
Statistical analysis
Statistical significance was assessed using Student’s t-test when
two groups were compared, and P50.05 was considered
significant.
Data availability
The authors confirm that the data supporting the findings of this
study are available within the article and its Supplementary
material.
Results
Gene discovery and variant assessment
In the framework of a research project aiming to end the diagnos-
tic odyssey in patients with neurogenetic diseases (URD-Cat,
Undiagnosed Rare Diseases Consortium of Catalonia), we per-
formed whole-exome sequencing and identified biallelic variants
in PI4KA in two patients (Patients 1 and 2) affected with hypomye-
linating leukodystrophy. Patient 1 was a compound heterozygote
for a missense variant and a loss-of-function variant
(p.Glu1152Lys, p.Pro876SerfsTer36), while Patient 2 harboured a
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homozygous missense variant (p.Gly1925Arg) located close to the
PI4KA catalytic site, suggesting possible consanguinity. Through
GeneMatcher,14 we recruited eight additional patients from inde-
pendent families carrying biallelic variants in PI4KA with compat-
ible phenotypes (Figs 1 and 2). Accordingly, the pLI value of PI4KA
was 0.00031, and the pRec value was 1, indicating that biallelic
deleterious variants in this gene are pathogenic.18 All identified
variants were ultra-rare with minor allele frequencies (MAF)
50.00001 in the Genome Aggregation Database (gnomAD)
(Supplementary Table 1). Eight patients were compound heterozy-
gous, while two [Patient 2, p.(Gly1925Arg) and Patient 8,
p.(Asp1854Asn)] were homozygous. Twelve of the identified var-
iants were missense variants, one was an in-frame deletion of one
amino acid, and the remaining four variants were predicted to re-
sult in loss-of-function. All missense/in-frame variants affected
conserved amino acids and were predicted to be deleterious by
various prediction tools (Table 1 and Supplementary Fig. 1). PI4KA
contains an a-solenoid domain, a dimerization domain, and a ‘cra-
dle’ domain (which contains three contact surfaces with TTC7,
with which PI4KA interacts directly), as well as a catalytic domain
at the C-terminus that is responsible for phosphorylation activity
and is anchored at the cell membrane.2,3 Interestingly, 7 of 13 con-
served missense/in-frame variants were clustered near the active
site of PI4KA in the catalytic and ‘cradle’ domains (Fig. 1C and
Supplementary Fig. 2). All patients harbouring one loss-of-function
variant were compound heterozygotes with a missense or in-
frame variant, with no patients harbouring two loss-of-function
variants. Patients 4 and 9 shared one of the truncating variants
(p.Thr2053SerfsTer4) but displayed discordant phenotypes. Patient
9, who carried an in-frame variant near the catalytic domain of the
second allele had a milder presentation, showing spastic parapar-
esis with an age of onset of 17. Patient 4 harboured a missense
variant in the a-solenoid domain and presented with severe hypo-
myelinating leukodystrophy with onset at 1 year of age.
Clinical features
We studied 10 patients harbouring biallelic, ultrarare and probably
deleterious variants after in silico predictions in PI4KA. Table 1 out-
lines the main clinical features of the patients, and the
Supplementary material includes the patients’ clinical summaries
and demographics. Weight, length and cranial circumference were
all normal at birth, while at the last examination (median age
7 years; 3–42 years), three patients (Patients 1, 2 and 6) had low
weight, four (Patients 1, 3, 6 and 8) had short height and four
(Patients 2, 3, 6 and 8) had a head circumference less than two
standard deviations (SD) below the mean. The median age of dis-
ease onset was 2 years (birth to 17 years).
Based on neurological involvement, patients in this cohort fall
into two main groups.
Group 1
Patients with developmental encephalopathy with hypomyelinat-
ing leukodystrophy/delayed myelination and structural brain
anomalies (Patients 1–8). These patients presented global develop-
mental delay in the first 12 months of life; in five of these patients,
clinical manifestations started in the neonatal period, mainly seiz-
ures and/or severe hypotonia. At the last examination (3–19 years
of age), all of the patients presented moderate-to-severe intellec-
tual disability, except for Patient 5, in whom intellectual disability
was mild. Four patients were non-verbal, and four had not
achieved ambulation, with Patient 3 being non-ambulatory even at
the age of 13 years. Axial hypotonia with limb spasticity and pyram-
idal signs were present in all patients except Patient 2, in whom
severe global hypotonia predominated and a neurophysiological
study performed at 11 months of age showed axonal sensory neur-
opathy. Six patients had cerebellar ataxia, and five presented a
movement disorder, including tremor in two patients, dystonia in
two patients, choreoathetosis in one patient and stereotypies in
another patient. There were no formal diagnoses of behavioural
disorders, but two patients showed hyperexcitable behaviour. Six
patients developed epileptic seizures, which appeared in the neo-
natal period in four patients and were very frequent initially but
became less frequent later. Patient 6 remained without seizures
after stopping antiepileptic treatment at 18 months of age.
Seizures were generalized, focal and myoclonic, and in Patient 1,
episodes suggestive of infantile spasms were described at
3.5 months of age. In Patients 1–3, seizures usually appeared to be
associated with fever or microbial infections and could evolve into
status epilepticus. The EEG results of Patients 1 and 2 showed
multifocal epileptiform discharges, with paracentral predomin-
ance being observed in Patient 1, which improved over time, and
slow background activity. In Patient 4, frontotemporal spike-wave
discharges were reported, and in Patient 8, bilateral frontal anoma-
lies evolved into marked abnormalities of background activity and
frequent diffuse spike and spike-wave discharges; however, in the
other three patients, interictal EEG was normal.
Other clinical features included nystagmus in four patients,
strabismus in two patients, and myopia and bilateral iris and ret-
inal coloboma in one patient. Sensorineural hearing loss was
reported in one patient. Four patients had feeding difficulties in
early childhood, and two required nasogastric tube feeding during
the first weeks of life. Patients 2, 3, 5 and 8 had immunological
problems, including hypogammaglobulinaemia in three patients
and lymphopaenia and autoimmune neutropaenia in one patient
each. It is worth noting that symptoms of bowel dysfunction (vom-
iting, diarrhoea, constipation or gastroesophageal reflux disease)
were reported in Patients 3, 5, 7 and 8. Finally, Patients 2, 6 and 8
presented abnormalities of the genito-urinary system, such as
cryptorchidism, renal cysts and duplication of the collecting
system.
Group 2
Patients with predominant spastic paraparesis (Patients 9 and 10).
These patients presented a milder phenotype characterized by
progressive spastic paraparesis with onset at 2 and 17 years and
pes cavus. One showed mild intellectual disability, and the other
patient had normal cognition. Patient 9 received a diagnosis of
Crohn’s disease with a stenosing-inflammatory pattern and cor-
ticosteroid-dependent course at 21 years of age.
Brain MRI findings
The MRI images of all the patients are shown in Fig. 2. Group 1
patients showed a pattern of marked, diffuse supratentorial and
infratentorial hypomyelination associated with white matter atro-
phy and a thin corpus callosum (Patients 1–4), incomplete/delayed
myelination (Patients 5–7) and bilateral perisylvian polymicrogyria
(Patient 8). The corpus callosum was dysplastic in Patients 3, 5 and
6. In Patients 1, 4 and 6, there was brainstem and cerebellar hypo-
plasia/atrophy, which remained unchanged up to age 2 in Patient
1. In addition, there was a component of cerebellar atrophy that
progressed in successive controls in Patients 3, 4 and 7 (inferior
lobe). The severity of myelin involvement correlated with clinical
manifestations, which were more severe in Patients 1–3. In con-
trast, cerebral neuroimaging in the clinically milder patients
(Patients 9 and 10) was normal, except for an arachnoid cyst of the
posterior fossa in Patient 9, which was considered an unrelated
finding. However, in these patients (and in Patients 1–3), cranial
MRI revealed cervical spinal cord atrophy.
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Figure 1 PI4KA variant features. (A) Family trees. Square = male; circle = female; filled symbols = affected individuals; open symbols = unaffected
carriers; WT = wild-type allele. (B) Structure of PI4KA protein and the mutations identified in this study. Top: Missense/in-frame variants. Bottom:
Loss-of-function variants. Light blue = a-solenoid domain; cyan = dimerization domain; dark blue = ‘cradle’ domain; dark purple = catalytic domain.
(C) 3D representation of the PI4KA catalytic domain. Blue = PI4KA; green = TTC7B; pink = A1, PI4KA inhibitor occupying the ATP-binding space in the
catalytic domain. The red balls represent the location of the missense/in-frame variants found in our cohort. Note the clustering of missense/in-
frame variants near the catalytic site of PI4KA.
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PI4KA activity in vitro and in vivo
We were able to obtain skin biopsies and/or blood samples from
Patients 1,3, 4, 9 and 10, and performed functional analysis of their
variants. Western blot analysis showed that the expression of the
PI4KA protein was strongly decreased in the fibroblasts of Patients
1, 3, 4, 9 and 10 compared to those of age-matched controls (Fig.
3B). This result was supported by immunofluorescence images
(Fig. 3C and D). To evaluate the activity of PI4KA, we used an anti-
body against the head group of its reaction product, PI(4)P, as pre-
viously described.2 Immunofluorescence revealed lower levels of
PI(4)P in our patients’ fibroblasts (Fig. 3C and D). Finally, we also
performed lipidomics analysis to quantify global phosphoinositide
(PI, PIP and PIP2) levels in Patients 1, 2, 9 and 10. All of the patients
showed a significantly decreased PIP/PI ratio compared to age-
matched control subjects, indicating decreased PI4KA activity in
these patients (Fig. 3E).
Discussion
We describe here a novel neurological syndrome caused by bial-
lelic mutations in the PI4KA gene. The clinical spectrum ranges
from a neurodevelopmental disorder of neonatal onset associated
Figure 2 MRI features of patients harbouring biallelic PI4KA variants. Left: Axial T1-weighted sequences. Middle: Axial T2-weighted sequences. Right:
Sagittal T1-weighted sequences. Patients 1 and 2 exhibited diffuse hypomyelination, global white matter atrophy with posterior predominance, a
thin corpus callosum and colpocephaly. Patient 1 also presented with brainstem and cerebellar hypoplasia. Patients 3 and 4 had diffuse hypomyeli-
nation with a thin corpus callosum and progressive cerebellar atrophy. Patient 4 also had brainstem atrophy. Patients 5–7 exhibited delayed myelin-
ation with mild ventriculomegaly. Patients 5 and 6 showed a dysplastic corpus callosum. Patient 6 had brainstem and cerebellar atrophy and Patient
7 exhibited atrophy of the cerebellar inferior lobe. Patient 8 showed bilateral perisylvian polymicrogyria. Patients 9 and 10 showed cervical spinal
cord atrophy, and arachnoid cyst of the posterior fossa was observed in Patient 9, the images of whom were otherwise normal.
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with severe hypomyelinating leukodystrophy with pontocerebellar
hypoplasia (or even polymicrogyria in one case) to spastic parapar-
esis beginning in adolescence. This cohort illustrates how muta-
tions in genes causing childhood leukodystrophies at the most
severe end of the clinical spectrum, can also give rise to milder
presentations, such as juvenile or adult-onset spastic paraplegias.
TUBB4A-related leukodystrophy, X-linked adrenoleukodystrophy,
Pelizaeus-Merzbacher disease and Alexander disease are paradigmat-
ic for this well-described phenomenon.19–24 Although in most cases
recessive mutations in this gene will manifest as hypomyelinating
Figure 3 PI4KA activity evaluation. (A) Schematic representation of P4KA pathway. (B) Western blot of PI4KA protein and quantification. Patients’
fibroblasts (n = 5) and controls (CTL, n = 5). (C) Immunofluorescence of PI4KA protein and the head group of the lipid PI(4)P and (D) its quantification
on a minimum of 100 cells. Patient’s fibroblasts (n = 5) and controls (CTL, n = 4). (E) Targeted lipidomics against phosphatidylinositol (PI), PIP and PIP2,
in human PBMCs from control (CTL) children (n = 5), control adults (n = 5); and PI4KA deficient patients (n = 4). Data represented as mean ± SD.
*P5 0.05, **P5 0.01, ***P5 0.001 (two-tailed Student’s t-test). Box plot centre line corresponds to the median, lower and upper limits to the first and
third quartiles (25th and 75th percentiles), respectively, and whiskers to 1.5 the interquartile range.
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leukodystrophy, we propose the term ‘PI4KA-spectrum’ to describe
the different neurological conditions associated with this gene.
Pyramidal tract involvement with increased limb muscle tone
predominates in most of the patients in this cohort. Remarkably,
Patient 2 shows severe global hypotonia with areflexia and abnor-
mal nerve conduction studies, indicating peripheral nervous sys-
tem involvement, which is in line with the neuropathy described
in a mouse model with Pi4ka inactivation restricted to Schwann
cells.25 In comparison with patients with mutations in FAM126A
(HCC), another member of the PI4KA/TTC7/FAM126A complex,2
four of our patients had an earlier clinical onset in the neonatal
period and were neurologically more severely affected.
Furthermore, epilepsy appears to be more common than in HCC
patients,26 and immunological or gastrointestinal symptoms have
not been reported in patients with HCC. On the other hand, it is
striking that none of the patients in the present study developed
cataracts, which suggests that their presence may be directly due
to malfunction of FAM126A. Peripheral neuropathy is an invariable
feature of HCC, whereas it was only observed in one of the patients
reported here. Regarding neuroimaging, Patient 4 exhibited a
hypomyelinating pattern with a more conspicuous periventricular
T2 hyperintensity, similar to the pattern described in patients with
FAM126A mutations.26 In contrast, the polymicrogyria and brain-
stem and cerebellar hypoplasia reported in our cohort have not
been described in FAM126A patients.
Further differential diagnosis should be made with other dis-
eases associated with hypomyelination, mainly PLP1 disorders,
and specifically disorders that present with cerebellar atrophy or
hypoplasia, such as Pol III-related disorders, 18q syndrome,
TUBB4A- and RARS-associated hypomyelination and hereditary
spastic paraplegia (both pure and complex forms). Disorders that
cause pontocerebellar hypoplasia and myelination delay should
also be taken into account.27 The combination of severe develop-
mental delay, motor impairment and early-onset seizures is a fea-
ture of developmental and epileptic encephalopathies (DEEs), and
patients with these diseases often show posterior fossa anomalies,
cerebral dysgenesis or delayed myelination. Hence, this group of
diseases should also be considered.28 Finally, other disorders asso-
ciated with neuronal migration and polymicrogyria should be
included in the differential diagnosis.29,30
Previously, mutations in PI4KA were reported in three foetuses
from a single family who showed bilateral polymicrogyria with
hypoplasia/dysplasia of the cerebellum, olivary and dentate nu-
cleus abnormalities, joint contractures and overlapping fingers.31
All three foetuses were compound heterozygous for two loss-of-
function variants: a premature stop variant [p.(Arg796Ter)] and a
missense variant located in the active site that abrogated kinase
activity [p.(Asp1854Asn)]. Therefore, the phenotypes presented by
these foetuses may represent the most severe end of the pheno-
typic spectrum of diseases associated with PI4KA mutations since
no abnormalities were detected during pregnancy in our cases.
This suggests that our patients may retain higher residual PI4KA
activity than previously reported patients.31 In support of this hy-
pothesis, Pi4ka mouse models harbouring two complete loss-of-
function alleles are embryonic lethal,5 while pi4ka knockdown
zebrafish, which retain some Pi4ka activity, show multiple devel-
opmental abnormalities.4 Interestingly, the only patient in our
study who shared a variant with the family reported by
Pagnamenta et al.31 [p.(Asp1854Asn)] also developed polymicrogy-
ria, suggesting that this variant may be specifically associated
with this developmental brain anomaly. Furthermore, the fact that
this variant in homozygosity leads to a milder phenotype than the
foetuses in Pagnamenta et al.,31 who had the p.Asp1854Asn variant
in compound heterozygous state with a stop codon variant,
strongly suggests that this missense variant would not cause a
complete loss-of-function, and a certain degree of residual PI4KA
activity is retained. Despite a clear enrichment of missense var-
iants close to PI4KA’s active site hence supporting the pathogenic
role of these variants, we did not find a patient with two loss-of-
function alleles, suggesting that the missense variants identified
in this cohort may be hypomorphic. Patients 1, 4, 5 and 9 har-
boured loss-of-function variants (out-of-frame indels or stop var-
iants) that were always in trans with missense variants located far
from the active site [p.(Glu1152Lys), p.(Asp1664Asn),
p.(Ala1198Thr)] or small in-frame mutations [Patient 9,
p.(Glu1820del)], suggesting that the impairment of PI4KA activity
resulting from these variants may have been less severe than that
caused by other variants. Two patients harbouring the
p.(Thr2053SerfsTer4) variant presented different phenotypes, indi-
cating that p.(Ala1198Thr) (Patient 4) might be more deleterious
than p.(Glu1820del) (Patient 9); however, phenotype-genotype cor-
relation in a small cohort of patients poses a challenge.
Although the clinical manifestations presented by our cohort of
patients were prominently neurological, five patients presented
with an immune disorder and/or a history of recurrent infections.
On the other hand, one patient suffered from Crohn’s disease,
whereas more non-specific manifestations, such as vomiting, diar-
rhoea, constipation or gastroesophageal reflux disease, were pre-
sent in four patients. It is tempting to speculate that some of these
extraneurological manifestations could be caused by disruption
of the interactions between PI4KA and TTC7A, defects that have
been associated with immunodeficiency and gastrointestinal
manifestations.32
The pathogenic effects of PI4KA mutations remain poorly
understood. PI4KA and PI(4)P levels were significantly diminished
in the fibroblasts of five patients. PI(4,5)P2, a product of PI(4)P phos-
phorylation, is a substrate for the PI3K-AKT-mTOR pathway,
which is critical for the myelination process.2,8 PIP levels were
reduced in the PBMCs of four patients, and specifically PI(4)P was
diminished as shown in fibroblasts of five patients, suggesting
that their use as biomarkers for diagnosis and prognosis may be
indicated. Moreover, and given the important role of PI(4)P in the
transport of phosphatidylserine, a phospholipid abundantly found
in myelin, to the plasma membrane,33,34 PI4KA malfunction may
lead to disturbances in the brain cell membrane lipidome, result-
ing in aberrant myelination. Concordantly, PI4KA inhibition has
been shown to significantly reduce phosphatidylserine levels in
cultured cells by inhibiting its transport to the plasma membrane,
a phenomenon also observed in Lenz-Majewski syndrome, a de-
velopmental condition that involves similar abnormalities in
PI(4)P/phosphatidylserine metabolism.35 Furthermore, inositol
phospholipids are also important in processes such as actin
remodelling and oligodendrocyte membrane polarization, which
are essential for myelination. This process is similar to the actin
polymerization-depolymerization sequence required for correct
cell migration during brain development25 and may underlie both
the myelination and neurodevelopmental defects we describe
(polymicrogyria and brainstem-cerebellar hypoplasia). Interesting-
ly, mice with knockout of Pi4k2a, another kinase involved in PI(4)P
formation from PI, develop late-onset features resembling heredi-
tary spastic paraplegia, and the inhibition of PI4K activity disrupts
the retrograde axonal transport of neurotrophins.36 The alteration
of axonal transport is one of the main processes involved in her-
editary spastic paraplegia37 and is also dependent on oligodendro-
cyte function.38
Given that lipid metabolism defects appear to play an import-
ant role in the pathophysiology of PI4KA-associated disorders and
other leukodystrophies and hereditary spastic paraplegias, thera-
peutic avenues for these patients could involve normalization of
lipidic disturbances impacting myelination.39,40 Alternatively,
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upregulation of PI4KA expression or treatment with drugs that
specifically treat secondary deficiencies in interacting proteins
(TTC7B and FAM126A) may prove helpful in alleviating symptoms
in the most severe patients in the future.41,42
In summary, we describe a novel inherited error of metabolism
caused by PI4KA malfunction resulting in a broad phenotypic spec-
trum ranging from severe global neurodevelopmental delay asso-
ciated with hypomyelinating leukodystrophy and/or brain
developmental anomalies such as pontocerebellar hypoplasia/at-
rophy (or even polymicrogyria) in the most severe forms to spastic
paraplegia in milder cases. The presence of immunological defi-
cits, gastrointestinal manifestations or genito-urinary abnormal-
ities may be helpful for the diagnosis of these patients.
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